MedTrace Logo

Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis

NCT07239102 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-11-20

No results posted yet for this study

Summary

This is a clinical retrospective study that will collect and analyze clinical data from all patients treated with fumeitinib mesylate in the Oncology Department of Tiantan Hospital between January 1, 2020 and May 31, 2025. The data collection will include general demographic characteristics (gender, age, family history, smoking history, etc.), clinicopathological features, NGS test reports, fumeitinib initiation time and dosage, concomitant medications, local treatments (surgery, radiotherapy, etc.), and baseline and follow-up imaging examinations related to efficacy and safety. The study will conduct: 1) clinical data analysis; and 2) exploration of resistance-related clinical characteristics and influencing factors.

Conditions

  • EGFR Positive Non-small Cell Lung Cancer
  • Central Nervous System Metastasis
  • Leptomeningeal Metastasis

Interventions

DRUG

Firmonertinib

Firmonertinib any dose, oral

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2025-05-01
Completion
2025-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07239102 on ClinicalTrials.gov